Alamar Biosciences became newly publicly traded after a $220 million IPO and reported a Q1 2026 revenue surge that nearly doubled year over year. The proteomics company posted $26.0 million in revenue versus $13.1 million in Q1 2025, driven by stronger product and instrument demand tied to its NULISA platform. Alamar reported product revenue of $21.3 million and noted instruments revenue rose 80% as well as consumables nearly tripling, indicating expanding usage among academic research and biopharma customers. At the same time, the company’s net loss widened to $21.3 million, alongside higher R&D and SG&A spend following its public-market transition. The company pointed to “rapid global traction” for NULISA and said it began 2026 with its record quarter. The update provides an early read-through on whether proteomics platforms can scale usage and recurring consumables quickly after market access. For the diagnostics and enabling-tech segment, the result matters because it shows IPO-era demand translating into instruments and consumables uptake rather than only top-line services.